Can-Fite BioPharma Ltd. (CANF) Return on equity 2017–2025
Can-Fite BioPharma Ltd. (CANF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-175.8%FY2025 · since FY2017: -162.3% → -175.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -175.8% | -30.8 pp |
| FY2024 | -145.0% | -22.7 pp |
| FY2023 | -122.3% | +105.2 pp |
| FY2022 | -227.5% | -139.8 pp |
| FY2021 | -87.7% | +150.1 pp |
| FY2020 | -237.8% | +279.2 pp |
| FY2019 | -517.0% | -299.1 pp |
| FY2018 | -217.9% | -55.7 pp |
| FY2017 | -162.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice